pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

274 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints580BioPharma Dive223onclive165BioSpace55Fierce Biotech54raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Nobel Laureate Jennifer Doudna enters AI protein design arena
    Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene-editing, is dipping her toes into a new, buzzy field: AI-powered pro…
    Fierce Biotech · 11d ago↗ source
  • Why early de-risking is redefining the path to IND
    Lonza explains why early de-risking has become a strategic imperative for biotech teams working to reach IND with confidence.
    Fierce Biotech · 11d ago↗ source
  • Understanding Agentic AI in Clinical Development
    Earlier this year, my colleague Matt Harrington suggested that clinical leaders should stop asking whether their organizations have an “AI strategy”, not because strategy doesn’t matter, but becaus…
    Fierce Biotech
← prev
page 5 of 11
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
· 11d ago
↗ source
  • Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
    The Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line standard-of-care regimen for non-small cell lung cancer, according to Leerink Par…
    BioSpace · 11d ago↗ source
  • Why Axiom hopes it’s ‘solved 2 major potholes’ that have hurt other stem cell biotechs
    When Axiom's stem cell therapy demonstrated a 0% mortality rate over two years in potentially fatal newborn neurological diseases this week, the biotech's leadership saw a broader validation for th…
    Fierce Biotech · 11d ago↗ source
  • BIO San Diego 2026 Executive Interviews
    Every year, the BIO International Convention brings together more than 20,000 leaders from across the global life sciences ecosystem.
    Fierce Biotech · 12d ago↗ source
  • Building a workforce engine for biomanufacturing
    Ohio’s $30M training initiative aims to scale talent pipelines and power life sciences growth statewide.
    Fierce Biotech · 13d ago↗ source
  • De-Risking a Rare Disease Launch Starts with Precision
    Why traditional models fall short in rare disease commercialization—and what works instead.
    Fierce Biotech · 1mo ago↗ source
  • <![CDATA[Dr Meeks on a Real-World Study of BCG Retreatment After BCG Failure in NMIBC]]>
    <![CDATA[Joshua J. Meeks, MD, PhD, discusses data from a real-world study of BCG retreatment after BCG failure in NMIBC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Hafron on a Multidisciplinary Quality Initiative Designed to Mitigate the AEs of ADT in Prostate Cancer]]>
    <![CDATA[Jason Hafron, MD, discusses findings from a study that evaluated the implementation of a multidisciplinary quality initiative in prostate cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Preoperative Intravesical Mitomycin-C Before TURBT Cuts Recurrence Risk by 77% in NMIBC Over 5 Years]]>
    <![CDATA[Two doses of intravesical mitomycin-C administered before TURBT produced a 77% reduction in the risk of recurrence or death vs TURBT alone in NMIBC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Genomic Disease Burden Markers, PD-L1 Expression Predictive of pOR With Neoadjuvant Gem-iDRS ± Cetrelimab in MIBC]]>
    <![CDATA[A biomarker analysis of SunRISe-4 found that high baseline TMB, GBD, and PD-L1 expression were associated with pathologic overall response to the regimen. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Croll on Radiographic Size Change vs irRVT After Neoadjuvant Therapy in RCC]]>
    <![CDATA[Benjamin Croll, MD, discusses findings from a study of the correlation between radiographic response and pathologic response in RCC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Approves T-DXd for Early-Stage HER2+ Breast Cancer]]>
    <![CDATA[The FDA approved trastuzumab deruxtecan for the adjuvant and neoadjuvant treatment of select early-stage HER2-positive breast cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Garzotto on Aglatimagene Besadenovec Plus Valacyclovir and EBRT in Localized Prostate Cancer]]>
    <![CDATA[Mark Garzotto, MD, discusses efficacy data with aglatimagene besadenovec plus valacyclovir and EBRT in localized prostate cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Cirstea on Sequencing Considerations in R/R Multiple Myeloma]]>
    <![CDATA[Diana Cirstea, MD, discusses sequencing considerations in relapsed/refractory multiple myeloma in the era of T-cell–redirecting therapies.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Hafron on the FDA Approval of Adjuvant Atezolizumab in MRD+ MIBC]]>
    <![CDATA[Jason Hafron, MD, discusses the significance of the FDA approval of adjuvant atezolizumab for MRD+ muscle-invasive bladder cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Durvalumab Plus BCG Reduces High-Risk NMIBC Recurrence or Death Risk by 32% in Phase 3 POTOMAC Trial]]>
    <![CDATA[Durvalumab plus BCG induction and maintenance yielded an HR of 0.68 vs BCG alone for DFS in BCG-naive, high-risk non–muscle-invasive bladder cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Darolutamide Plus ADT Yields Significant OS Benefit in mHSPC]]>
    <![CDATA[Darolutamide plus ADT demonstrated a 50% reduction in the risk of death in metastatic hormone-sensitive prostate cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[OncLive Weekly News Quiz (5/15/2026): Did You Catch 3 New FDA Oncology Approvals?]]>
    <![CDATA[Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Pembrolizumab Plus BCG Elicits 92% CR Rate in BCG-Naive Very High-Risk T1 NMIBC]]>
    <![CDATA[Pembrolizumab plus BCG achieved a 92% 6-month complete response rate in very high-risk T1 bladder cancer with no progression to muscle-invasive disease.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder Cancer]]>
    <![CDATA[The FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Detalimogene Voraplasmid Yields 54% CR Rate in Heavily Pretreated BCG-Unresponsive NMIBC With CIS]]>
    <![CDATA[TRAEs were generally reversible and low grade, and 96.8% of patients remained free from progression to T2 or greater disease at the data cutoff. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Roswell Park Team Members Take Part in Global Conference Dedicated to Indigenous Peoples and Cancer]]>
    <![CDATA[Members of Roswell Park Comprehensive Cancer Center participated in the 2026 World Indigenous Cancer Conference.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Poll Findings Highlight the Most Anticipated GU Cancer Abstracts at ASCO 2026]]>
    <![CDATA[GU experts identified key abstracts of interest from the upcoming ASCO Annual Meeting via OncLive’s social media.]]>
    onclive · 2mo ago↗ source